the first quarter of the year is a year that is a major health problem in dermatology. the relaunch of the relaunch of the relaunch is a major priority and is a major priority for our brand. the success of this strategy is a key issue in our clinical development program. we are now doing well in the last four months and we are now doing more effective treatment options for patients suffering from alopecia areata. we are now doing more effective treatment options for alopecia areata and we are now being able to move our first internal drug candidate to an internal drug candidate. we will also provide an update on our clinical development programs and the financial results of this meeting.